Because of atypical responses, conventional Response Evaluation Criteria in Solid Tumors (RECIST) might underestimate the benefit of pembrolizumab in approximately 15% of patients treated for melanoma, a study published in the Journal of Clinical Oncology has shown.1
Scientific Publications
Scientific Journals for February 2016
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth Sandeep Dhayade, Susanne Kaesler, Tobias Sinnberg, Hyazinth Dobrowinski Stefanie Peters Ulrike Naumann He Liu Robert E. Hunger Martin Thunemann Tilo Biedermann Birgit…
Read More Number of Moles Not Always Related to Likelihood of Melanoma
The number of moles, or nevi, a patient had was not related to the likelihood that they had melanoma, according to the results of a new study published in JAMA Dermatology. In fact, the study found that most patients with melanoma had very few nevi and no atypical nevi.
Researchers Identify Drug That Could Treat Melanoma
Less than a year after mapping the genetic landscape of melanoma, a researcher from the University of California, Merced, has identified a drug that could be effective in battling the deadly skin cancer.
UC Merced Professor Fabian V. Filipp led a team of researchers on the new project, the results of which were published today (Feb. 29) in the journal Neoplasia.